In this open-label , randomised , phase 3 trial , we recruited patients aged 18-75 years with stage IV , histologically confirmed colorectal cancer , an Eastern Cooperative Oncology Group ( ECOG ) performance status of 0-2 , an estimated life expectancy of greater than 3 months , and adequate organ function , from centres in Germany and Austria .